title: Antitumor activity of human hydatid cyst fluid in a murine model of colon cancer.
abstract: This study evaluates the antitumor immune response induced by human hydatic cyst fluid (HCF) in an animal model of colon carcinoma. We found that anti-HCF antibodies were able to identify cell surface and intracellular antigens in CT26 colon cancer cells. In prophylactic tumor challenge experiments, HCF vaccination was found to be protective against tumor formation for 40% of the mice (P = 0.01). In the therapeutic setting, HCF vaccination induced tumor regression in 40% of vaccinated mice (P = 0.05). This vaccination generated memory immune responses that protected surviving mice from tumor rechallenge, implicating the development of an adaptive immune response in this process. We performed a proteomic analysis of CT26 antigens recognized by anti-HCF antibodies to analyze the immune cross-reactivity between E. granulosus (HCF) and CT26 colon cancer cells. We identified two proteins: mortalin and creatine kinase M-type. Interestingly, CT26 mortalin displays 60% homology with E. granulosus hsp70. In conclusion, our data demonstrate the capacity of HCF vaccination to induce antitumor immunity which protects from tumor growth in an animal model. This new antitumor strategy could open new horizons in the development of highly immunogenic anticancer vaccines.
authors.affiliation: Laboratorio de Glicobiología e Inmunología Tumoral, Institut Pasteur de Montevideo, 11400 Montevideo, Uruguay ; Clínica Quirúrgica 1, Hospital Pasteur, Facultad de Medicina, Universidad de la República, 11400 Montevideo, Uruguay.
authors.forename: Edgardo
authors.initials: E
authors.lastname: Berriel
authors.forename: Sofía
authors.initials: S
authors.lastname: Russo
authors.forename: Leticia
authors.initials: L
authors.lastname: Monin
authors.forename: María Florencia
authors.initials: MF
authors.lastname: Festari
authors.forename: Nora
authors.initials: N
authors.lastname: Berois
authors.forename: Gabriel
authors.initials: G
authors.lastname: Fernández
authors.forename: Teresa
authors.initials: T
authors.lastname: Freire
authors.forename: Eduardo
authors.initials: E
authors.lastname: Osinaga
mesh_terms: D056704:Adaptive Immunity; D000818:Animals; D000947:Antigens, Helminth / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D019496:Cancer Vaccines / Q000627:therapeutic use*; D045744:Cell Line, Tumor; D003110:Colonic Neoplasms / Q000276:immunology / Q000517:prevention & control*; D052283:Creatine Kinase, MM Form / Q000276:immunology; D003429:Cross Reactions; D004443:Echinococcosis / Q000276:immunology*; D048209:Echinococcus granulosus / Q000276:immunology; D018840:HSP70 Heat-Shock Proteins / Q000276:immunology; D006801:Humans; D051379:Mice; D040901:Proteomics
chemical_list: D000947:Antigens, Helminth; D000970:Antineoplastic Agents; D019496:Cancer Vaccines; D018840:HSP70 Heat-Shock Proteins; C080352:mortalin; D052283:Creatine Kinase, MM Form
references.citation: Cancer Lett. 1993 Aug 16;72(1-2):91-8
references.pmid: 8402581
references.citation: Cancer. 2003 Nov 1;98(9):1999-2000
references.pmid: 14584087
references.citation: Biochem Biophys Res Commun. 2012 Jun 29;423(2):411-6
references.pmid: 22683628
references.citation: J Clin Oncol. 2011 Dec 20;29(36):4828-36
references.pmid: 22042955
references.citation: Int J Cancer. 2010 Dec 15;127(12):2893-917
references.pmid: 21351269
references.citation: Ann N Y Acad Sci. 2007 Oct;1113:192-201
references.pmid: 17978282
references.citation: Int J Cancer. 2006 Jun 15;118(12):2973-80
references.pmid: 16425258
references.citation: Mol Biol Rep. 2013 Aug;40(8):4701-4
references.pmid: 23645038
references.citation: Nature. 2011 Dec 21;480(7378):480-9
references.pmid: 22193102
references.citation: PLoS One. 2011;6(9):e24407
references.pmid: 21931708
references.citation: IUBMB Life. 2007 Apr-May;59(4-5):269-73
references.pmid: 17505964
references.citation: J Immunol. 2013 Jan 1;190(1):469-78
references.pmid: 23225891
references.citation: J Immunol Methods. 2012 Aug 31;382(1-2):1-23
references.pmid: 22658969
references.citation: Mol Biochem Parasitol. 1995 Nov;74(2):245-50
references.pmid: 8719168
references.citation: PLoS Negl Trop Dis. 2010 Jul 06;4(7):e730
references.pmid: 20625551
references.citation: Parasite. 2012 May;19(2):101-15
references.pmid: 22348213
references.citation: Br Med J. 1980 Jul 19;281(6234):195-6
references.pmid: 7407519
references.citation: Parasite Immunol. 2003 Mar;25(3):119-26
references.pmid: 12911519
references.citation: J Parasitol Res. 2012;2012:304183
references.pmid: 22496957
references.citation: Immunology. 2006 Jun;118(2):271-8
references.pmid: 16771863
references.citation: J Innate Immun. 2010;2(3):238-47
references.pmid: 20375559
references.citation: Lancet Oncol. 2012 Jun;13(6):607-15
references.pmid: 22575588
references.citation: Clin Exp Immunol. 1995 Nov;102(2):281-5
references.pmid: 7586679
references.citation: Int J Urol. 2011 Feb;18(2):113-20
references.pmid: 21091799
references.citation: Melanoma Res. 2008 Jun;18(3):172-83
references.pmid: 18477891
references.citation: Exp Parasitol. 2001 Jun;98(2):100-9
references.pmid: 11465993
references.citation: Ann Surg. 1928 Oct;88(4):641-67
references.pmid: 17865976
references.citation: Carcinogenesis. 2001 May;22(5):737-40
references.pmid: 11323392
references.citation: Parasitology. 2005 Nov;131(Pt 5):669-77
references.pmid: 16255825
references.citation: J Pathol. 2005 Jan;205(1):74-81
references.pmid: 15532096
references.citation: Future Oncol. 2012 Dec;8(12):1529-35
references.pmid: 23231515
references.citation: Parasite Immunol. 2009 Nov;31(11):686-96
references.pmid: 19825108
references.citation: Cancer Lett. 2011 Jun 28;305(2):239-49
references.pmid: 20667649
references.citation: J Biol Chem. 1993 Mar 25;268(9):6615-21
references.pmid: 8454632
references.citation: J Biol Chem. 2003 May 30;278(22):20179-84
references.pmid: 12660242
references.citation: Clin Exp Immunol. 1995 Mar;99(3):433-9
references.pmid: 7882566